The Unequal Promise of Prostate Cancer Therapy

Triplet therapies that combine androgen deprivation therapy, infusion chemotherapy and oral hormones may extend the lives of patients with metastatic prostate cancer. But until researchers address inequities in drug trial enrollment, Black patients may not fully benefit from such advances, said Bryan Fitzgerald, PharmD, BCOP, an oncology clinical pharmacy specialist at the University of Rochester Medical Center, in New York, at the Hematology/Oncology Pharmacy Association Annual Conference